Ignite Creation Date:
2025-12-25 @ 3:18 AM
Ignite Modification Date:
2025-12-26 @ 1:57 AM
Study NCT ID:
NCT04075305
Status:
UNKNOWN
Last Update Posted:
2023-09-28
First Post:
2019-03-22
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D001943', 'term': 'Breast Neoplasms'}, {'id': 'D011471', 'term': 'Prostatic Neoplasms'}, {'id': 'D001932', 'term': 'Brain Neoplasms'}, {'id': 'D005833', 'term': 'Genital Neoplasms, Female'}, {'id': 'D011832', 'term': 'Radiation Injuries'}, {'id': 'D012004', 'term': 'Rectal Neoplasms'}, {'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D004938', 'term': 'Esophageal Neoplasms'}, {'id': 'D010190', 'term': 'Pancreatic Neoplasms'}, {'id': 'D006258', 'term': 'Head and Neck Neoplasms'}, {'id': 'D001749', 'term': 'Urinary Bladder Neoplasms'}, {'id': 'D008113', 'term': 'Liver Neoplasms'}], 'ancestors': [{'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D001941', 'term': 'Breast Diseases'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D005834', 'term': 'Genital Neoplasms, Male'}, {'id': 'D014565', 'term': 'Urogenital Neoplasms'}, {'id': 'D005832', 'term': 'Genital Diseases, Male'}, {'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D011469', 'term': 'Prostatic Diseases'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}, {'id': 'D016543', 'term': 'Central Nervous System Neoplasms'}, {'id': 'D009423', 'term': 'Nervous System Neoplasms'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D005831', 'term': 'Genital Diseases, Female'}, {'id': 'D052776', 'term': 'Female Urogenital Diseases'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D014947', 'term': 'Wounds and Injuries'}, {'id': 'D015179', 'term': 'Colorectal Neoplasms'}, {'id': 'D007414', 'term': 'Intestinal Neoplasms'}, {'id': 'D005770', 'term': 'Gastrointestinal Neoplasms'}, {'id': 'D004067', 'term': 'Digestive System Neoplasms'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D005767', 'term': 'Gastrointestinal Diseases'}, {'id': 'D007410', 'term': 'Intestinal Diseases'}, {'id': 'D012002', 'term': 'Rectal Diseases'}, {'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D004935', 'term': 'Esophageal Diseases'}, {'id': 'D004701', 'term': 'Endocrine Gland Neoplasms'}, {'id': 'D010182', 'term': 'Pancreatic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D014571', 'term': 'Urologic Neoplasms'}, {'id': 'D001745', 'term': 'Urinary Bladder Diseases'}, {'id': 'D014570', 'term': 'Urologic Diseases'}, {'id': 'D008107', 'term': 'Liver Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D011878', 'term': 'Radiotherapy'}], 'ancestors': [{'id': 'D013812', 'term': 'Therapeutics'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 8000}, 'targetDuration': '2 Years', 'patientRegistry': True}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'startDateStruct': {'date': '2019-02-01', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2023-09', 'completionDateStruct': {'date': '2025-05-01', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2023-09-25', 'studyFirstSubmitDate': '2019-03-22', 'studyFirstSubmitQcDate': '2019-08-28', 'lastUpdatePostDateStruct': {'date': '2023-09-28', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2019-08-30', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-02-01', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Progression-free Survival', 'timeFrame': '3 months after MR-Linac treatment', 'description': 'Progression free survival of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care practices.'}, {'measure': 'Progression-free Survival', 'timeFrame': '6 months after MR-Linac treatment', 'description': 'Progression free survival of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care practices.'}, {'measure': 'Progression-free Survival', 'timeFrame': '24 months after MR-Linac treatment', 'description': 'Progression free survival of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care practices.'}, {'measure': 'Survival', 'timeFrame': '3 months after MR-Linac treatment', 'description': 'Overall survival of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care practices.'}, {'measure': 'Survival', 'timeFrame': '6 months after MR-Linac treatment', 'description': 'Overall survival of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care practices.'}, {'measure': 'Survival', 'timeFrame': '24 months after MR-Linac treatment', 'description': 'Overall survival of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care practices.'}, {'measure': 'Disease-free Survival', 'timeFrame': '3 months after MR-Linac treatment', 'description': 'Disease-free survival of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care practices.'}, {'measure': 'Disease-free Survival', 'timeFrame': '6 months after MR-Linac treatment', 'description': 'Disease-free survival of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care practices.'}, {'measure': 'Disease-free Survival', 'timeFrame': '24 months after MR-Linac treatment', 'description': 'Disease-free survival of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care practices.'}, {'measure': 'Patient reported Health related quality of life (HRQoL).', 'timeFrame': '3 months after treatment.', 'description': 'Patient reported health related quality of life is captured through a questionnaire the Generic European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30. They include 5 functional scales (physical, role, emotional, cognitive and social), three symptom scales, a global health scale, and six single items. All of these scales and items measures range in score from 0 to 100. A high score on functional or global health status scale represents a high/healthy level of functioning. A high score for a symptom scale represents a high level of symptomatology.'}, {'measure': 'Patient reported Health related quality of life (HRQoL).', 'timeFrame': '6 months after treatment.', 'description': 'Patient reported health related quality of life is captured through a questionnaire the Generic European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30. They include 5 functional scales (physical, role, emotional, cognitive, and social), three symptom scales, a global health scale, and six single items. All of these scales and items measures range in score from 0 to 100. A high score on functional or global health status scale represents a high/healthy level of functioning. A high score for a symptom scale represents a high level of symptomatology.'}, {'measure': 'Patient reported Health related quality of life (HRQoL).', 'timeFrame': '12 months after treatment.', 'description': 'Patient reported health related quality of life is captured through a questionnaire the Generic European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30. They include 5 functional scales (physical, role, emotional, cognitive and social), three symptom scales, a global health scale, and six single items. All of these scales and items measures range in score from 0 to 100. A high score on functional or global health status scale represents a high/healthy level of functioning. A high score for a symptom scale represents a high level of symptomatology.'}, {'measure': 'Patient reported Health related quality of life (HRQoL).', 'timeFrame': '24 months after treatment.', 'description': 'Patient reported health related quality of life is captured through a questionnaire the Generic European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30. They include 5 functional scales (physical, role, emotional, cognitive and social), three symptom scales, a global health scale, and six single items. All of these scales and items measures range in score from 0 to 100. A high score on functional or global health status scale represents a high/healthy level of functioning. A high score for a symptom scale represents a high level of symptomatology.'}, {'measure': 'Patient reported Health related quality of life (HRQoL).', 'timeFrame': '3 months after treatment.', 'description': "Generic patient reported quality of life is captured by The EuroQol (EQ)-5D-5L questionnaire. This includes a descriptive system questionnaire and visual analogue scale (VAS). The descriptive system scores five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) from 1 to 5 where 1 means having no problems, and 5 means extreme problems or unable to participate. The digits can be combined in a 5-digit code to describe the overall health status. For example, 12111. The VAS records the overall current health on a vertical visual analogue scale from 0 to 100, respectively 'the worst health you can imagine' to 'the best health you can imagine'."}, {'measure': 'Patient reported Health related quality of life (HRQoL).', 'timeFrame': '6 months after treatment.', 'description': "Generic patient reported quality of life is captured by The EuroQol (EQ)-5D-5L questionnaire. This includes a descriptive system questionnaire and visual analogue scale (VAS). The descriptive system scores five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) from 1 to 5 where 1 means having no problems, and 5 means extreme problems or unable to participate. The digits can be combined in a 5-digit code to describe the overall health status. For example, 12111. The VAS records the overall current health on a vertical visual analogue scale from 0 to 100, respectively 'the worst health you can imagine' to 'the best health you can imagine'."}, {'measure': 'Patient reported Health related quality of life (HRQoL).', 'timeFrame': '12 months after treatment.', 'description': "Generic patient reported quality of life is captured by The EuroQol (EQ)-5D-5L questionnaire. This includes a descriptive system questionnaire and visual analogue scale (VAS). The descriptive system scores five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) from 1 to 5 where 1 means having no problems, and 5 means extreme problems or unable to participate. The digits can be combined in a 5-digit code to describe the overall health status. For example, 12111. The VAS records the overall current health on a vertical visual analogue scale from 0 to 100, respectively 'the worst health you can imagine' to 'the best health you can imagine'."}, {'measure': 'Patient reported Health related quality of life (HRQoL).', 'timeFrame': '24 months after treatment.', 'description': "Generic patient reported quality of life is captured by The EuroQol (EQ)-5D-5L questionnaire. This includes a descriptive system questionnaire and visual analogue scale (VAS). The descriptive system scores five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) from 1 to 5 where 1 means having no problems, and 5 means extreme problems or unable to participate. The digits can be combined in a 5-digit code to describe the overall health status. For example, 12111. The VAS records the overall current health on a vertical visual analogue scale from 0 to 100, respectively 'the worst health you can imagine' to 'the best health you can imagine'."}, {'measure': 'Patient reported tumor specific quality of life (QoL).', 'timeFrame': '3 months after treatment.', 'description': 'Disease-specific patient reported quality of life is captured by a tumor specific EORTC QLQ questionnaire. (Brain-BN20, Breast-BR23, Bladder-BLM30, colorectal-CR29, Gynecological-CX24\\&VU34, Head and Neck-HN35, liver-HCC18 (primary) and -LMC21 (metastasis), lung-LC13, esophageal-OES18, prostate-PR2, pancreas-PAN26). They all include a different set of functional scales and symptom scales. All of these scales and items measures range in score from 0 to 100. A high score on functional scale represents a high/healthy level of functioning. A high score for a symptom scale represents a high level of symptomatology.'}, {'measure': 'Patient reported tumor specific quality of life (QoL).', 'timeFrame': '6 months after treatment.', 'description': 'Disease-specific patient reported quality of life is captured by a tumor specific EORTC QLQ questionnaire. (Brain-BN20, Breast-BR23, Bladder-BLM30, colorectal-CR29, Gynecological-CX24\\&VU34, Head and Neck-HN35, liver-HCC18 (primary) and -LMC21 (metastasis), lung-LC13, esophageal-OES18, prostate-PR2, pancreas-PAN26). They all include a different set of functional scales and symptom scales. All of these scales and items measures range in score from 0 to 100. A high score on functional scale represents a high/healthy level of functioning. A high score for a symptom scale represents a high level of symptomatology.'}, {'measure': 'Patient reported tumor specific quality of life (QoL).', 'timeFrame': '12 months after treatment.', 'description': 'Disease-specific patient reported quality of life is captured by a tumor specific EORTC QLQ questionnaire. (Brain-BN20, Breast-BR23, Bladder-BLM30, colorectal-CR29, Gynecological-CX24\\&VU34, Head and Neck-HN35, liver-HCC18 (primary) and -LMC21 (metastasis), lung-LC13, esophageal-OES18, prostate-PR2, pancreas-PAN26). They all include a different set of functional scales and symptom scales. All of these scales and items measures range in score from 0 to 100. A high score on functional scale represents a high/healthy level of functioning. A high score for a symptom scale represents a high level of symptomatology.'}, {'measure': 'Patient reported tumor specific quality of life (QoL).', 'timeFrame': '24 months after treatment.', 'description': 'Disease-specific patient reported quality of life is captured by a tumor specific EORTC QLQ questionnaire. (Brain-BN20, Breast-BR23, Bladder-BLM30, colorectal-CR29, Gynecological-CX24\\&VU34, Head and Neck-HN35, liver-HCC18 (primary) and -LMC21 (metastasis), lung-LC13, esophageal-OES18, prostate-PR2, pancreas-PAN26). They all include a different set of functional scales and symptom scales. All of these scales and items measures range in score from 0 to 100. A high score on functional scale represents a high/healthy level of functioning. A high score for a symptom scale represents a high level of symptomatology.'}, {'measure': 'Acute toxicity in common toxicity criteria for adverse events (CTCAE).', 'timeFrame': '3 months after treatment.', 'description': 'Disease-specific toxicity is obtained from the hospital information system. Toxicities are reported according to the Common Terminology Criteria for Adverse Events (CTCAE) dictionary.'}, {'measure': 'Acute toxicity in common toxicity criteria for adverse events (CTCAE).', 'timeFrame': '6 months after treatment.', 'description': 'Disease-specific toxicity is obtained from the hospital information system. Toxicities are reported according to the Common Terminology Criteria for Adverse Events (CTCAE) dictionary.'}, {'measure': 'Acute toxicity in common toxicity criteria for adverse events (CTCAE).', 'timeFrame': '12 months after treatment.', 'description': 'Disease-specific toxicity is obtained from the hospital information system. Toxicities are reported according to the Common Terminology Criteria for Adverse Events (CTCAE) dictionary.'}, {'measure': 'Acute toxicity in common toxicity criteria for adverse events (CTCAE).', 'timeFrame': '24 months after treatment.', 'description': 'Disease-specific toxicity is obtained from the hospital information system. Toxicities are reported according to the Common Terminology Criteria for Adverse Events (CTCAE) dictionary.'}, {'measure': 'Clinical tumor response.', 'timeFrame': '2 year follow up.', 'description': 'Clinical tumor response in participating patients is obtained from hospital information systems. Clinical patient follow-up and re-staging procedures are conducted to local standard of care practices.'}, {'measure': 'Pathological tumor response.', 'timeFrame': '2 year follow up.', 'description': 'Pathological tumor response in participating patients who undergo surgery are obtained from hospital information systems. Clinical patient follow-up and re-staging procedures are conducted to local standard of care practices.'}, {'measure': 'Toxicity in common toxicity criteria for adverse events (CTCAE).', 'timeFrame': '2 years', 'description': 'Disease-specific toxicity is obtained from the hospital information system.'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': True}, 'conditionsModule': {'conditions': ['Oncology', 'Breast Cancer', 'Prostate Cancer', 'Gynecologic Cancer', 'Brain Tumor', 'Brain Cancer', 'Gynecologic Tumor', 'Prostate Tumor', 'Prostate Neoplasm', 'Breast Tumor', 'Radiation Toxicity', 'Quality of Life', 'Rectal Cancer', 'Rectal Tumor', 'Rectal Neoplasms', 'Lung Cancer', 'Lung Tumor', 'Lung Neoplasm', 'Esophageal Cancer', 'Esophagus Cancer', 'Esophageal Tumor', 'Esophageal Neoplasm', 'Esophagus Tumor', 'Esophagus Neoplasm', 'Pancreatic Cancer', 'Pancreatic Tumor', 'Pancreatic Neoplasms', 'Head and Neck Cancer', 'Head and Neck Neoplasms', 'Head and Neck Tumor', 'Tumor', 'Neoplasms', 'Bladder Cancer', 'Bladder Neoplasm', 'Liver Cancer', 'Liver Neoplasms', 'Liver Metastases', 'Oligometastases']}, 'referencesModule': {'references': [{'pmid': '34981300', 'type': 'DERIVED', 'citation': 'Tan H, Stewart J, Ruschin M, Wang MH, Myrehaug S, Tseng CL, Detsky J, Husain Z, Chen H, Sahgal A, Soliman H. Inter-fraction dynamics during post-operative 5 fraction cavity hypofractionated stereotactic radiotherapy with a MR LINAC: a prospective serial imaging study. J Neurooncol. 2022 Feb;156(3):569-577. doi: 10.1007/s11060-021-03938-w. Epub 2022 Jan 3.'}, {'pmid': '33014774', 'type': 'DERIVED', 'citation': 'de Mol van Otterloo SR, Christodouleas JP, Blezer ELA, Akhiat H, Brown K, Choudhury A, Eggert D, Erickson BA, Faivre-Finn C, Fuller CD, Goldwein J, Hafeez S, Hall E, Harrington KJ, van der Heide UA, Huddart RA, Intven MPW, Kirby AM, Lalondrelle S, McCann C, Minsky BD, Mook S, Nowee ME, Oelfke U, Orrling K, Sahgal A, Sarmiento JG, Schultz CJ, Tersteeg RJHA, Tijssen RHN, Tree AC, van Triest B, Hall WA, Verkooijen HM. The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy. Front Oncol. 2020 Sep 7;10:1328. doi: 10.3389/fonc.2020.01328. eCollection 2020.'}]}, 'descriptionModule': {'briefSummary': "The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose to improve patients' survival, local, and regional tumor control and quality of life.", 'detailedDescription': 'Rationale: Radiation therapy has become indispensable in cancer treatment. However, it is associated with severe side effects. Innovation in radiation therapy has resulted in the development of MR-guided radiation therapy (MRGRT) which allows high precision radiotherapy under real time MR visualization. High precision MRGRT has the potential of dose escalation and margin reduction and may potentially lead to higher cure rates and less toxicity. MRGRT can be delivered by the MRI guided Linear Accelerator (MR-Linac) which integrates a state-of-the-art linear accelerator, 1.5T diagnostic quality MRI and an online adaptive workflow.\n\nObjective: The Multi-OutcoMe EvaluatioN of radiation Therapy Using the MR-Linac Study (MOMENTUM) aims to accelerate the technical and clinical development of Anatomic and Biologic MRGRT and facilitate the evidence-based introduction of the MR-Linac into clinical practice. In MOMENTUM, technical and clinical data are gathered in order to optimize software, evaluate treatment outcomes, toxicities and progression free, disease free, and overall survival per disease site, and create a repository of anatomical and biological MR sequences to develop new features.\n\nStudy design: A multi-institutional, international observational cohort study. Study population: Cancer patients ≥ 18 years receiving treatment and/or imaging on an MR-Linac machine are eligible for enrollment.\n\nMain study parameters/endpoints: MOMENTUM will collect technical and clinical patient data. The technical patient data is defined as data generated by (the use of) the MR-Linac and will include data collection during scans performed during routine care as well as research MRIs. Clinical data will be categorized into six classes: demographic, disease characteristics, treatment classifiers, toxicity outcomes, cancer control outcomes and PROs.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'Patients receiving treatment and/or imaging on an MR-Linac machine are eligible for enrolment. Patients must meet eligibility criteria and provide informed consent to be enrolled.', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Patient is to undergo or has completed imaging or treatment procedures on an MR-Linac;\n* Patient provides written, informed consent;\n* Patient is 18 years old or older.\n\nExclusion Criteria:\n\n* MRI exclusion criteria, including\n* MRI contraindications as per usual clinical care, such as (possible) pregnancy; claustrophobia and metal or electronic implants not compatible with MRI.'}, 'identificationModule': {'nctId': 'NCT04075305', 'acronym': 'MOMENTUM', 'briefTitle': 'The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study', 'organization': {'class': 'OTHER', 'fullName': 'UMC Utrecht'}, 'officialTitle': 'The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study', 'orgStudyIdInfo': {'id': 'NL66650.041.18'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Brain cancer', 'interventionNames': ['Radiation: Radiation therapy']}, {'label': 'Lung cancer', 'interventionNames': ['Radiation: Radiation therapy']}, {'label': 'Esophageal cancer', 'interventionNames': ['Radiation: Radiation therapy']}, {'label': 'Breast Cancer', 'interventionNames': ['Radiation: Radiation therapy']}, {'label': 'Head and Neck Cancer', 'interventionNames': ['Radiation: Radiation therapy']}, {'label': 'Pancreatic cancer', 'interventionNames': ['Radiation: Radiation therapy']}, {'label': 'Gynecological cancer', 'interventionNames': ['Radiation: Radiation therapy']}, {'label': 'Rectal cancer', 'interventionNames': ['Radiation: Radiation therapy']}, {'label': 'Prostate cancer', 'interventionNames': ['Radiation: Radiation therapy']}, {'label': 'Bladder cancer', 'interventionNames': ['Radiation: Radiation therapy']}, {'label': 'Oligometastases', 'interventionNames': ['Radiation: Radiation therapy']}, {'label': 'Liver cancer', 'interventionNames': ['Radiation: Radiation therapy']}, {'label': 'Other types of cancer', 'interventionNames': ['Radiation: Radiation therapy']}], 'interventions': [{'name': 'Radiation therapy', 'type': 'RADIATION', 'description': 'Radiation therapy on the CE marked and FDA approved MR-Linac', 'armGroupLabels': ['Bladder cancer', 'Brain cancer', 'Breast Cancer', 'Esophageal cancer', 'Gynecological cancer', 'Head and Neck Cancer', 'Liver cancer', 'Lung cancer', 'Oligometastases', 'Other types of cancer', 'Pancreatic cancer', 'Prostate cancer', 'Rectal cancer']}]}, 'contactsLocationsModule': {'locations': [{'zip': '15212', 'city': 'Pittsburgh', 'state': 'Pennsylvania', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Tom Colonias', 'role': 'CONTACT'}], 'facility': 'Allegheny Health Network', 'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}, {'zip': '77030', 'city': 'Houston', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Clifton D Fuller', 'role': 'CONTACT', 'email': 'cdfuller@mdanderson.org', 'phone': '713-745-4404'}], 'facility': 'Md Anderson Cancer Center', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '53226', 'city': 'Milwaukee', 'state': 'Wisconsin', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'William A Hall', 'role': 'CONTACT'}], 'facility': 'Medical College of Wisconsin', 'geoPoint': {'lat': 43.0389, 'lon': -87.90647}}, {'city': 'Melbourne', 'status': 'NOT_YET_RECRUITING', 'country': 'Australia', 'contacts': [{'name': 'Sweet Ping', 'role': 'CONTACT'}], 'facility': 'Austin Health - Olivia Newton-John Cancer Wellness and Research Centre', 'geoPoint': {'lat': -37.814, 'lon': 144.96332}}, {'city': 'Brussels', 'status': 'NOT_YET_RECRUITING', 'country': 'Belgium', 'contacts': [{'name': 'Robbe van den Begin', 'role': 'CONTACT'}], 'facility': 'Insitut Jules Bordet', 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}, {'city': 'Toronto', 'state': 'Ontario', 'status': 'RECRUITING', 'country': 'Canada', 'contacts': [{'name': 'Arjun Sahgal', 'role': 'CONTACT'}], 'facility': 'Sunnybrook Health Sciences Centre/Odette Cancer Centre', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}, {'city': 'Toronto', 'status': 'RECRUITING', 'country': 'Canada', 'contacts': [{'name': 'Michael Velec', 'role': 'CONTACT'}], 'facility': 'University Health Network - Princess Margaret Cancer Center', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}, {'zip': '5000', 'city': 'Odense', 'state': 'Funen', 'status': 'RECRUITING', 'country': 'Denmark', 'contacts': [{'name': 'Tine Schytte', 'role': 'CONTACT', 'email': 'Tine.Schytte@rsyd.dk'}], 'facility': 'Odense Universitetshospital', 'geoPoint': {'lat': 55.39594, 'lon': 10.38831}}, {'city': 'Tübingen', 'status': 'RECRUITING', 'country': 'Germany', 'contacts': [{'name': 'Cihan Gani', 'role': 'CONTACT'}], 'facility': 'Universitätsklinikum Tübingen', 'geoPoint': {'lat': 48.52266, 'lon': 9.05222}}, {'city': 'Brescia', 'status': 'NOT_YET_RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Stefano Magrini', 'role': 'CONTACT'}], 'facility': 'Università degli Studi di Brescia', 'geoPoint': {'lat': 45.53558, 'lon': 10.21472}}, {'city': 'Negrar', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Filippo Alongi', 'role': 'CONTACT'}], 'facility': 'IRCCS Ospedale Sacro Cuore Don Calabria', 'geoPoint': {'lat': 45.52918, 'lon': 10.93899}}, {'city': 'Amsterdam', 'status': 'RECRUITING', 'country': 'Netherlands', 'contacts': [{'name': 'Marlies N Nowee', 'role': 'CONTACT'}], 'facility': 'Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital', 'geoPoint': {'lat': 52.37403, 'lon': 4.88969}}, {'city': 'Deventer', 'status': 'RECRUITING', 'country': 'Netherlands', 'contacts': [{'name': 'Paul Jeene', 'role': 'CONTACT'}], 'facility': 'Radiotherapiegroep', 'geoPoint': {'lat': 52.255, 'lon': 6.16389}}, {'city': 'Leeuwarden', 'status': 'NOT_YET_RECRUITING', 'country': 'Netherlands', 'contacts': [{'name': 'Peter de Boer', 'role': 'CONTACT'}], 'facility': 'Radiotherapeutisch Instituut Friesland (RIF)', 'geoPoint': {'lat': 53.20271, 'lon': 5.80973}}, {'city': 'Nijmegen', 'status': 'RECRUITING', 'country': 'Netherlands', 'contacts': [{'name': 'Linda Kerkmeijer', 'role': 'CONTACT'}], 'facility': 'Radboud UMC', 'geoPoint': {'lat': 51.8425, 'lon': 5.85278}}, {'zip': '3508GA', 'city': 'Utrecht', 'status': 'RECRUITING', 'country': 'Netherlands', 'contacts': [{'name': 'Helena M Verkooijen, Prof, Dr', 'role': 'CONTACT', 'email': 'h.m.verkooijen@umcutrecht.nl'}, {'name': 'Tessa Leer', 'role': 'CONTACT', 'email': 'T.Leer@umcutrecht.nl'}, {'name': 'Tessa Leer', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Helena M Verkooijen, Prof, Dr', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University Medical Center Utrecht', 'geoPoint': {'lat': 52.09083, 'lon': 5.12222}}, {'city': 'London', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Shaista Hafeez', 'role': 'CONTACT'}], 'facility': 'The Royal Marsden and The Institute of Cancer Research National Institute for Health Research Biomedical Research Centre', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'city': 'Manchester', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Ananya Choudhury', 'role': 'CONTACT'}], 'facility': 'The Christie National Health Service Foundation Trust', 'geoPoint': {'lat': 53.48095, 'lon': -2.23743}}], 'centralContacts': [{'name': 'Tessa Leer', 'role': 'CONTACT', 'email': 'T.Leer@umcutrecht.nl', 'phone': 'T +31 (0)88 75 63707'}], 'overallOfficials': [{'name': 'Helena M Verkooijen, Prof, Dr', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Universitair Medical Centre Utrecht'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'UMC Utrecht', 'class': 'OTHER'}, 'collaborators': [{'name': 'The Netherlands Cancer Institute', 'class': 'OTHER'}, {'name': 'Sunnybrook Health Sciences Centre', 'class': 'OTHER'}, {'name': 'M.D. Anderson Cancer Center', 'class': 'OTHER'}, {'name': 'The Christie NHS Foundation Trust', 'class': 'OTHER'}, {'name': 'Royal Marsden NHS Foundation Trust', 'class': 'OTHER'}, {'name': 'Medical College of Wisconsin', 'class': 'OTHER'}, {'name': 'Elekta Limited', 'class': 'INDUSTRY'}, {'name': 'Odense University Hospital', 'class': 'OTHER'}, {'name': 'Radboud University Medical Center', 'class': 'OTHER'}, {'name': 'Radiotherapiegroep', 'class': 'OTHER'}, {'name': 'Jules Bordet Institute', 'class': 'OTHER'}, {'name': 'University Hospital Tuebingen', 'class': 'OTHER'}, {'name': 'Radiotherapeutic Institute Friesland', 'class': 'OTHER'}, {'name': 'Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)', 'class': 'OTHER'}, {'name': 'IRCCS Sacro Cuore Don Calabria di Negrar', 'class': 'OTHER'}, {'name': 'Austin Health', 'class': 'OTHER_GOV'}, {'name': 'Princess Margaret Hospital, Canada', 'class': 'OTHER'}, {'name': 'Università degli Studi di Brescia', 'class': 'OTHER'}], 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Prof. Dr.', 'investigatorFullName': 'Helena M Verkooijen', 'investigatorAffiliation': 'UMC Utrecht'}}}}